Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.

TitleImatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
Publication TypeJournal Article
Year of Publication2014
AuthorsGordon J, Udeh U, Doobay K, Magro C, Wildman H, Davids M, Mersten JN, Huang W-T, Lyman S, Crow MK, Spiera RF
JournalClin Exp Rheumatol
Volume32
Issue6 Suppl 86
PaginationS-189-93
Date Published2014 Nov-Dec
ISSN0392-856X
KeywordsAdult, Antirheumatic Agents, Benzamides, Calcium Channel Blockers, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Hydroxychloroquine, Imatinib Mesylate, Lung Diseases, Interstitial, Male, Middle Aged, Piperazines, Prednisone, Protein Kinase Inhibitors, Proton Pump Inhibitors, Pyrimidines, Respiratory Function Tests, Scleroderma, Diffuse, Treatment Outcome
Abstract

OBJECTIVES: We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc).

METHODS: In this open-label, single-arm, extension-phase clinical trial, patients continued imatinib for 24 months following 12 months of initial treatment.

RESULTS: Seventeen patients were enrolled. Forty of 92 adverse events (AE) and 0/6 serious (S) AEs were possibly related to medication. The MRSS decreased from a median of 21 to 16, (p=0.002).

CONCLUSIONS: This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc.

Alternate JournalClin Exp Rheumatol
PubMed ID25152211
Related Faculty: 
Cynthia M. Magro, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700